149 related articles for article (PubMed ID: 37858804)
21. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
Guo Z; Lu X; Yang F; Qin L; Yang N; Wu J; Wang H
Eur J Med Res; 2022 Aug; 27(1):148. PubMed ID: 35953852
[TBL] [Abstract][Full Text] [Related]
23. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours.
McEwan C; Owen J; Stride E; Fowley C; Nesbitt H; Cochrane D; Coussios CC; Borden M; Nomikou N; McHale AP; Callan JF
J Control Release; 2015 Apr; 203():51-6. PubMed ID: 25660073
[TBL] [Abstract][Full Text] [Related]
24. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer.
Jang HS; Koo KC; Cho KS; Chung BH
Yonsei Med J; 2016 Sep; 57(5):1070-8. PubMed ID: 27401636
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.
Chen Y; Xu Z; Lu T; Luo J; Xue H
Drug Deliv; 2022 Dec; 29(1):2705-2712. PubMed ID: 35980107
[TBL] [Abstract][Full Text] [Related]
26. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
[TBL] [Abstract][Full Text] [Related]
27. Effect of docetaxel-loaded lipid microbubble in combination with ultrasound-triggered microbubble destruction on the growth of a gastric cancer cell line.
Lai B; Zhu P; Li H; Hu L; Wang J
Oncol Lett; 2019 Jul; 18(1):442-448. PubMed ID: 31289515
[TBL] [Abstract][Full Text] [Related]
28. Ultrasound imaging guided targeted sonodynamic therapy enhanced by magnetophoretically controlled magnetic microbubbles.
Zhu Y; Arkin G; He T; Guo F; Zhang L; Wu Y; Prasad PN; Xie Z
Int J Pharm; 2024 Apr; 655():124015. PubMed ID: 38527565
[TBL] [Abstract][Full Text] [Related]
29. Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy.
Carson AR; McTiernan CF; Lavery L; Grata M; Leng X; Wang J; Chen X; Villanueva FS
Cancer Res; 2012 Dec; 72(23):6191-9. PubMed ID: 23010078
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
31. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors.
Kang J; Wu X; Wang Z; Ran H; Xu C; Wu J; Wang Z; Zhang Y
J Ultrasound Med; 2010 Jan; 29(1):61-70. PubMed ID: 20040776
[TBL] [Abstract][Full Text] [Related]
33. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Kassem L; Shohdy KS; Abdel-Rahman O
Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
[TBL] [Abstract][Full Text] [Related]
34.
Çalışkan SÖ; Aslan C; Duran ÖF; Kaya İ; Özen H
Turkiye Parazitol Derg; 2022 Sep; 46(3):172-179. PubMed ID: 36094116
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
Shimamoto N; Ito M; Chiba M; Honma S; Imazu H; Sumiyama K
Hepatobiliary Pancreat Dis Int; 2020 Oct; 19(5):478-485. PubMed ID: 32265136
[TBL] [Abstract][Full Text] [Related]
36. Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Maiorano BA; De Giorgi U; Roviello G; Messina C; Altavilla A; Cattrini C; Mennitto A; Maiello E; Di Maio M
ESMO Open; 2022 Oct; 7(5):100575. PubMed ID: 36152486
[TBL] [Abstract][Full Text] [Related]
37. Exploiting a Rose Bengal-bearing, oxygen-producing nanoparticle for SDT and associated immune-mediated therapeutic effects in the treatment of pancreatic cancer.
Nicholas D; Nesbitt H; Farrell S; Logan K; McMullin E; Gillan T; Kelly P; O'Rourke D; Porter S; Thomas K; O'Hagan BMG; Nomikou N; Callan B; Callan JF; McHale AP
Eur J Pharm Biopharm; 2021 Jun; 163():49-59. PubMed ID: 33798727
[TBL] [Abstract][Full Text] [Related]
38. Oxygen-sufficient lipid nanobubbles combined with UTMD for enhanced sonodynamic therapy of Hep-G2 cells.
Tan H; Tian Y; Yang H; Liu Z; Liang X; Li B; Cheng W
J Biomed Mater Res B Appl Biomater; 2021 Nov; 109(11):1796-1806. PubMed ID: 33838006
[TBL] [Abstract][Full Text] [Related]
39. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Wenzel M; Hoeh B; Chun FKH; Mandel P
Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
